This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO 2019 - Grohé Poster
Let's collaborate Boehringer Ingelheim

ESMO 2019 - Grohé Poster

Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients following treatment with immune checkpoint inhibitors: updated results of the ongoing non-interventional study VARGADO (NCT02392455)

Grohé C, Gleiber W, Haas S, Krüger S, Schulze M, Atz J, Kaiser R​

 

ESMO 2019 VARGADO Grohe poster

Related articles

Learn more about the science behind this presentation in the papers and other materials below

Nintedanib* plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma

Grohé et al. Future Oncology 2019; DOI 10.2217/fon-2019-0262

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

Corral J et al. CTO 2019; DOI: 10.1007/s12094-019-02053-7

Related information

About Nintedanib

A detailed look at nintedanib’s mechanism of action and the role of angiogenesis in cancer

Preliminary data on nintedanib after immune checkpoint inhibitors

Preliminary data on use of nintedanib plus docetaxel after chemotherapy and ICI therapy

ESMO 2019

Find information about Boehringer Ingelheim’s activities at ESMO 2019
Back to top

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: September 2019